Top-Line Results for Genentech/ Immunogen's T-DM1 No Surprise
By Catherine Shaffer
Monday, April 2, 2012
The Genentech Inc. unit of Roche AG announced that its Phase III (EMILIA) trial of Immunogen Inc.-partnered asset trastuzumab emtansine (T-DM1) showed positive results. Patients randomized to treatment with T-DM1 had a significantly longer duration of progression-free survival than those receiving the control therapy, lapatinib plus capecitabine.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.